

World Journal of *Gastrointestinal Oncology*

World J Gastrointest Oncol 2022 October 15; 14(10): 1892-2087



MINIREVIEWS

- 1892** Go-Ichi-Ni-San 2: A potential biomarker and therapeutic target in human cancers
Shan DD, Zheng QX, Chen Z
- 1903** Neoadjuvant therapy in resectable pancreatic cancer: A promising curative method to improve prognosis
Zhang HQ, Li J, Tan CL, Chen YH, Zheng ZJ, Liu XB

ORIGINAL ARTICLE

Basic Study

- 1918** Transcriptional factor III A promotes colorectal cancer progression by upregulating cystatin A
Wang J, Tan Y, Jia QY, Tang FQ
- 1933** VCAN, expressed highly in hepatitis B virus-induced hepatocellular carcinoma, is a potential biomarker for immune checkpoint inhibitors
Wang MQ, Li YP, Xu M, Tian Y, Wu Y, Zhang X, Shi JJ, Dang SS, Jia XL
- 1949** Overexpression of ELL-associated factor 2 suppresses invasion, migration, and angiogenesis in colorectal cancer
Feng ML, Wu C, Zhang HJ, Zhou H, Jiao TW, Liu MY, Sun MJ
- 1968** Interleukin-34 promotes the proliferation and epithelial-mesenchymal transition of gastric cancer cells
Li CH, Chen ZM, Chen PF, Meng L, Sui WN, Ying SC, Xu AM, Han WX
- 1981** Cuproptosis-related long non-coding RNAs model that effectively predicts prognosis in hepatocellular carcinoma
Huang EM, Ma N, Ma T, Zhou JY, Yang WS, Liu CX, Hou ZH, Chen S, Zong Z, Zeng B, Li YR, Zhou TC

Retrospective Study

- 2004** Multi-slice spiral computed tomography in differential diagnosis of gastric stromal tumors and benign gastric polyps, and gastric stromal tumor risk stratification assessment
Li XL, Han PF, Wang W, Shao LW, Wang YW
- 2014** Predictive value of a serum tumor biomarkers scoring system for clinical stage II/III rectal cancer with neoadjuvant chemoradiotherapy
Zhao JY, Tang QQ, Luo YT, Wang SM, Zhu XR, Wang XY

Observational Study

- 2025** Role of sex on psychological distress, quality of life, and coping of patients with advanced colorectal and non-colorectal cancer
Pacheco-Barcia V, Gomez D, Obispo B, Mihic Gongora L, Hernandez San Gil R, Cruz-Castellanos P, Gil-Raga M, Villalba V, Ghanem I, Jimenez-Fonseca P, Calderon C

- 2038** Droplet digital polymerase chain reaction assay for methylated ring finger protein 180 in gastric cancer

Guo GH, Xie YB, Jiang T, An Y

Prospective Study

- 2048** Long-term follow-up of HER2 overexpression in patients with rectal cancer after preoperative radiotherapy: A prospective cohort study

Chen N, Li CL, Peng YF, Yao YF

META-ANALYSIS

- 2061** Combining of chemotherapy with targeted therapy for advanced biliary tract cancer: A systematic review and meta-analysis

Bai XS, Zhou SN, Jin YQ, He XD

CASE REPORT

- 2077** Disseminated carcinomatosis of the bone marrow caused by granulocyte colony-stimulating factor: A case report and review of literature

Fujita K, Okubo A, Nakamura T, Takeuchi N

CORRECTION

- 2085** Correction to "Genome-wide CRISPR-Cas9 screening identifies that hypoxia-inducible factor-1 α -induced CBX8 transcription promotes pancreatic cancer progression *via* IRS1/AKT axis"

Teng BW, Zhang KD, Yang YH, Guo ZY, Chen WW, Qiu ZJ

ABOUT COVER

Editorial Board of *World Journal of Gastrointestinal Oncology*, Sezer Saglam, MD, Full Professor, Medical Oncology, Demiroglu Bilim University, Istanbul 34349, Turkey. saglam@istanbul.edu.tr

AIMS AND SCOPE

The primary aim of *World Journal of Gastrointestinal Oncology* (WJGO, *World J Gastrointest Oncol*) is to provide scholars and readers from various fields of gastrointestinal oncology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJGO mainly publishes articles reporting research results and findings obtained in the field of gastrointestinal oncology and covering a wide range of topics including liver cell adenoma, gastric neoplasms, appendiceal neoplasms, biliary tract neoplasms, hepatocellular carcinoma, pancreatic carcinoma, cecal neoplasms, colonic neoplasms, colorectal neoplasms, duodenal neoplasms, esophageal neoplasms, gallbladder neoplasms, *etc.*

INDEXING/ABSTRACTING

The WJGO is now abstracted and indexed in PubMed, PubMed Central, Science Citation Index Expanded (SCIE, also known as SciSearch®), Journal Citation Reports/Science Edition, Scopus, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2022 edition of Journal Citation Reports® cites the 2021 impact factor (IF) for WJGO as 3.404; IF without journal self cites: 3.357; 5-year IF: 3.250; Journal Citation Indicator: 0.53; Ranking: 162 among 245 journals in oncology; Quartile category: Q3; Ranking: 59 among 93 journals in gastroenterology and hepatology; and Quartile category: Q3. The WJGO's CiteScore for 2021 is 3.6 and Scopus CiteScore rank 2021: Gastroenterology is 72/149; Oncology is 203/360.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: *Ying-Yi Yuan*; Production Department Director: *Xiang Li*; Editorial Office Director: *Jia-Ru Fan*.

NAME OF JOURNAL

World Journal of Gastrointestinal Oncology

ISSN

ISSN 1948-5204 (online)

LAUNCH DATE

February 15, 2009

FREQUENCY

Monthly

EDITORS-IN-CHIEF

Monjur Ahmed, Florin Burada

EDITORIAL BOARD MEMBERS

<https://www.wjgnet.com/1948-5204/editorialboard.htm>

PUBLICATION DATE

October 15, 2022

COPYRIGHT

© 2022 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>



Correction to “Genome-wide CRISPR-Cas9 screening identifies that hypoxia-inducible factor-1a-induced CBX8 transcription promotes pancreatic cancer progression *via* IRS1/AKT axis”

Bu-Wei Teng, Kun-Dong Zhang, Yu-Han Yang, Zeng-Ya Guo, Wei-Wei Chen, Zheng-Jun Qiu

Specialty type: Oncology

Provenance and peer review:

Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): A
Grade B (Very good): B
Grade C (Good): C
Grade D (Fair): 0
Grade E (Poor): 0

P-Reviewer: Liu H, United States;
Solimando AG, Italy; Trna J, Czech Republic

Received: April 6, 2022

Peer-review started: April 6, 2022

First decision: June 12, 2022

Revised: June 15, 2022

Accepted: September 13, 2022

Article in press: September 13, 2022

Published online: October 15, 2022



Bu-Wei Teng, Department of General Surgery, Shanghai General Hospital of Nanjing Medical University, Shanghai 200080, China

Bu-Wei Teng, Department of General Surgery, Lianyungang Clinical College of Nanjing Medical University/The First People's Hospital of Lianyungang, Lianyungang 222061, Jiangsu Province, China

Kun-Dong Zhang, Yu-Han Yang, Zeng-Ya Guo, Wei-Wei Chen, Zheng-Jun Qiu, Department of General Surgery, Shanghai General Hospital, Shanghai 200080, China

Corresponding author: Zheng-Jun Qiu, MD, Chief Doctor, Director, Surgeon, Department of General Surgery, Shanghai General Hospital, No. 100 Haining Road, Shanghai 200080, China. zhengjun.qiu@shgh.cn

Abstract

Correction to “Genome-wide CRISPR-Cas9 screening identifies that hypoxia-inducible factor-1a-induced CBX8 transcription promotes pancreatic cancer progression *via* IRS1/ AKT axis” (PMID: 34853645 PMCID: PMC8603463 DOI: 10.4251/wjgo.v13.i11.1709). In this article, the picture of Figure 6C was misused due to our carelessness while typesetting. We corrected this mistake, and replaced the incorrect image with the correct one.

Key Words: Correction; Error; Figure; CRISPR-Cas9

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Correction to “Genome-wide CRISPR-Cas9 screening identifies that hypoxia-inducible factor-1a-induced CBX8 transcription promotes pancreatic cancer progression *via* IRS1/AKT axis.”

Citation: Teng BW, Zhang KD, Yang YH, Guo ZY, Chen WW, Qiu ZJ. Correction to “Genome-wide CRISPR-Cas9 screening identifies that hypoxia-inducible factor-1 α -induced CBX8 transcription promotes pancreatic cancer progression via IRS1/AKT axis”. *World J Gastrointest Oncol* 2022; 14(10): 2085-2087

URL: <https://www.wjgnet.com/1948-5204/full/v14/i10/2085.htm>

DOI: <https://dx.doi.org/10.4251/wjgo.v14.i10.2085>

TO THE EDITOR

After confirming the figures in our manuscript, we were surprised to find a mistake in Figure 6C[1]. It was an unintentional error that occurred when we typeset the images. We have replaced the incorrect images with the correct Figure 6C (Figure 1). Figure 6D-E was based on the correct image and does not need to be changed. We assure you that this mistake does not change the meaning of the picture or the conclusion of the manuscript. We apologize for our careless mistake, which has caused great inconvenience.



Figure 1 We replaced the incorrect images with the correct Figure 6C in “Genome-wide CRISPR-Cas9 screening identifies that hypoxia-inducible factor-1 α -induced CBX8 transcription promotes pancreatic cancer progression via IRS1/AKT axis.”

FOOTNOTES

Author contributions: Teng BW found and corrected the misused figure; Zhang KD, Yang YH, Guo ZY, Chen WW, and Qiu ZJ checked the correction.

Conflict-of-interest statement: There are no conflicts of interest to report.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country/Territory of origin: China

ORCID number: Bu-Wei Teng 0000-0002-9555-2830; Kun-Dong Zhang 0000-0002-2232-2153; Yu-Han Yang 0000-0002-3717-5088; Zeng-Ya Guo 0000-0001-8310-5147; Wei-Wei Chen 0000-0001-8325-5663; Zheng-Jun Qiu 0000-0002-8318-847X.

S-Editor: Chen YL

L-Editor: Filipodia

P-Editor: Chen YL

REFERENCES

- 1 **Teng BW**, Zhang KD, Yang YH, Guo ZY, Chen WW, Qiu ZJ. Genome-wide CRISPR-Cas9 screening identifies that hypoxia-inducible factor-1a-induced *CBX8* transcription promotes pancreatic cancer progression *via* IRS1/AKT axis. *World J Gastrointest Oncol* 2021; **13**: 1709-1724 [PMID: [34853645](#) DOI: [10.4251/wjgo.v13.i11.1709](#)]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: bpgoffice@wjgnet.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

